Vizsla Copper Corp is a junior exploration and developing company. Its projects are Woodjam, Poplar, Copperview, and Redgold. The Company operates in a single industry segment, mineral exploration, within the Canadian geographical segment.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- VCU is partnering with PSC Partners in the WIND-PSC initiative to find treatments for primary sclerosing cholangitis (PSC). - The five-year project aims to create a global database of 2,000 PSC patients, gathering medical data and quality of life reports. - The initiative seeks to accelerate treatment development by serving as a comparison cohort for clinical trials and improving disease biomarkers. - VCU will contribute data from over 100 patients to the study, supported by a $445,526 grant.
- A Phase 2 clinical trial of survodutide, a dual GLP-1 and glucagon agonist, demonstrated that up to 83% of patients with fatty liver disease showed measurable improvement after 48 weeks of treatment. - The study found that 75% of patients experienced disease resolution with significantly reduced liver inflammation, fat, and scarring, while 50% showed improved fibrosis and liver enzymes. - Survodutide represents a potential breakthrough for treating metabolic dysfunction-associated steatohepatitis (MASH), which affects one in four people globally and currently has only one FDA-approved treatment option. - The dual-agonist approach directly targets the liver while maintaining GLP-1 benefits, offering hope for patients with both fatty liver disease and obesity-related conditions.
